Paper Details

  1. Home
  2. Paper Details

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.

Author: DrilonAlexander, KangHyunseok, KhanSaad, KondaBhavana, OhashiKadoaki, OheYuichiro, SoldatenkovaVictoria, SpiraAlexander, SubbiahVivek, SullivanLoretta, SzymczakSylwia, TakedaMasayuki, WeissJared, WolfJürgen, WrightJennifer

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Selpercatinib, a RET kinase inhibitor, is being evaluated for its efficacy and safety in patients with RET fusion-positive advanced solid tumors, excluding lung and thyroid cancers.
Paper Details　
Original Abstract of the Article :
Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(22)00541-1

データ提供：米国国立医学図書館（NLM）

Selpercatinib: A Tumour-Agnostic Treatment Option

The field of oncology is constantly seeking new ways to effectively treat cancer. This study explores the potential of selpercatinib, a first-in-class RET kinase inhibitor, as a treatment option for patients with RET fusion-positive solid tumors. This study, known as the LIBRETTO-001 trial, is a phase 1/2, open-label, basket trial, designed to investigate the efficacy and safety of selpercatinib in a diverse group of patients with RET fusion-positive solid tumors, excluding those with lung or thyroid cancers. The findings reveal that selpercatinib demonstrates promising results in treating a variety of RET fusion-positive tumors, offering a potentially effective treatment option for patients with these rare cancers.

A New Frontier in Tumour-Agnostic Treatment

This research demonstrates the potential of selpercatinib as a tumour-agnostic treatment option. The drug's ability to effectively target RET fusion-positive tumors, regardless of their location, is a significant advancement in the field of oncology. This research offers hope for patients with rare cancers, who often face limited treatment options. The desert of cancer treatment is vast and complex, but with each discovery, we find new paths to healing.

Navigating the Desert of Cancer Treatment

Selpercatinib's potential as a tumour-agnostic treatment option is a promising development for patients with RET fusion-positive cancers. This research underscores the importance of ongoing research to identify effective treatments for rare cancers and explore new avenues for individualized therapy. The journey through the desert of cancer treatment is often challenging, but with continued innovation, we can find more effective treatments for patients.

Dr.Camel's Conclusion

This study showcases the potential of selpercatinib as a promising treatment option for patients with RET fusion-positive solid tumors, regardless of their location. This research offers a new frontier in the field of oncology, highlighting the potential for personalized and effective cancer treatment. The desert of cancer research is vast and challenging, but with each discovery, we move closer to finding cures and improving the lives of those affected by this disease.

Date :
  1. Date Completed 2022-10-03
  2. Date Revised 2022-12-27
Further Info :

Pubmed ID

36108661

DOI: Digital Object Identifier

10.1016/S1470-2045(22)00541-1

Related Literature

Article Analysis
・Effects of selpercatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.